πŸ“‹ Trump administration is funding US drone manufacturers through Pentagon's Strategic Capital Office, with an $1

medium convictionFirst mentioned Jan 3, 2026

Trump administration is funding US drone manufacturers through Pentagon's Strategic Capital Office, with an $1.1B program targeting 300k attack drones by 2027. Multiple companies across direct beneficiaries and supply chain stand to benefit.

Evidence & details
Evidence
  • +ONDS forward EV/revenue multiple ~28x, while AVAV was 8-9x and in Replicator program
  • +AIRO was at ~2.5x forward P/S when bought
  • +DPRO might be at 2.8x from some revenue calculations
Catalysts
  • ⚑Potential multiple compression for ONDS as peers trade at lower multiples
  • ⚑Replicator program involvement for AVAV and AIRO
Risks
  • βˆ’Personal opinion, not a formal analysis
  • βˆ’Multiples may vary
  • βˆ’Drones sector volatility

Chart

Post Timeline Β· 1 posts

new thesismedium

@bennybigbull Personally speaking, I feel like $ONDS is richly priced compared to other drone companies. I have $AVAV, $DPRO, $KTOS, and $AIRO for drone exposure. (Just going off the top of my head, dont take this too literally) Fwd EV/revenue multiples was ~28s+ now for Onda…

Thesis: ONDS is richly priced compared to other drone companies (AVAV, DPRO, KTOS, AIRO) based on forward EV/revenue multiples. Other drone companies offer higher upside.

view on X β†—ONDS Β· AVAV Β· DPRO Β· KTOS Β· AIRO
Current Price
$204.40
via cornerstones
Return from entry
β€”
entry Jan 3, 2026
Thesis Lifecycle
πŸ“
updatedJan 8, 2026+1 conv

Bullish on AVAV due to $800M+ contract win, successful use of switchblade drones in Venezuela, and tailwind from $1.5T+ defense spending, with upside from small market cap.

source β†—
πŸ“
updatedJan 12, 2026

AeroVironment is a prime beneficiary of increased military spending and geopolitical conflicts, with strong financials and unique drone capabilities.

source β†—
πŸ“
updatedJan 12, 2026-1 conv

User is bullish on both AVAV (offensive kamikaze drones) and AIRO (interceptor drones), covering both sides of drone warfare. They have been cost averaging up on AVAV and report strong performance in AIRO positions.

source β†—
⚠️
review neededJan 13, 2026

US government directive to leave Iran implies direct intervention, similar to previous use of GBU-57A/B MOPs and US invasion of Venezuela. These 'Department of War' stocks are positioned to profit from a US invasion of Iran.

source β†—
πŸ“
updatedJan 19, 2026

Greenland tariff dispute with Europe creates panic selling in US defense and semiconductor stocks, but these sectors are resilient and benefit from US national security and supply chain sovereignty, making them good dip-buying opportunities.

source β†—
πŸ“
updatedJan 19, 2026

ONDS is richly priced compared to other drone companies (AVAV, DPRO, KTOS, AIRO) based on forward EV/revenue multiples. Other drone companies offer higher upside.

source β†—
πŸ“
updatedJan 19, 2026+1 conv

Post asserts AVAV is the gold standard and already part of replicator, KTOS is also successful alongside it; AIRO offers highest potential for lowest downside risk in counter UAV replicator; DPRO is speculative with early-stage RKLB-like upside.

source β†—
πŸ“
updatedJan 20, 2026-1 conv

Despite tariff panic, fundamental buildout in defense, AI, and domestic hardware remains unchanged, presenting a valuation opportunity.

source β†—
πŸ“
updatedJan 20, 2026

AVAV is a great dip buy after 15% drop; primary revenue of $1B+ from switchblade replicator is strong, and panic over a $175M contract renegotiation is overblown.

source β†—
πŸ“
updatedJan 20, 2026+1 conv

Markets overreacted to SCAR program news; it's a contract renegotiation, not cancellation. AVAV's key program is Switchblade via Replicator.

source β†—
πŸ“
updatedJan 20, 2026

Market overreacted to SCAR program news; AVAV has strong fundamentals with recent large deals and DoD funding tailwinds.

source β†—
πŸ“
updatedJan 20, 2026

AVAV is misunderstood; the market overreacted to SCAR program news. The $1.4B+ in contracts and renegotiation to FFP terms indicate stronger long-term prospects.

source β†—
πŸ“
updatedJan 20, 2026

AVAV's contract renegotiation from R&D to long-term volume was misinterpreted as program cancellation, causing an unwarranted 17% selloff. Author added to position based on this thesis.

source β†—
πŸ“
updatedJan 24, 2026

Personal stock ratings with detailed commentary: Strong Buy on 14 stocks (SNAP, META, MU, TSM, etc.) citing catalysts like memory supercycle, bottlenecks, and AI tailwinds. Buy on 32 stocks including COIN, SMCI, GOOGL, and several crypto and drone plays. Questionable on VELO and SKYT due to weak fundamentals. Avoid on 11 stocks (UAVS, BKKT, PLTR, etc.) due to dilution, high debt, or overvaluation. Overall bullish on AI, memory, bottlenecks, made-in-America supply chains, and defense, with a long-term view until after midterms.

source β†—
πŸ“
updatedJan 29, 2026-2 conv

Potential near-term headwind for $AVAV due to government shutdown affecting government contractors.

source β†—
πŸ“
updatedFeb 2, 2026+1 conv

Update on multiple positions: VPG strong as 'hard carry' from Optimus thesis; AIRO breakeven after drop, thesis unchanged; LPTH down slightly on Germanium fix, long-term pivot unchanged; AVAV good long at $13-14B due to defense contracts scaling.

source β†—
πŸ“
updatedFeb 25, 2026

AVAV and oil stocks like CVX are hedges for potential US-Iran conflict; if war occurs they likely outperform, otherwise other sectors outperform.

source β†—
πŸ“
updatedFeb 28, 2026+1 conv

Israel's airstrike on Iran creates immediate bullish catalysts for energy and defense stocks due to increased geopolitical tensions and potential escalation.

source β†—
πŸ”΄
closedMar 25, 2026

Sold $AVAV at a solid six-figure loss and rotated capital into photonics.

source β†—
πŸ“
updatedMay 29, 2026-1 conv

Trump administration is funding US drone manufacturers through Pentagon's Strategic Capital Office, with an $1.1B program targeting 300k attack drones by 2027. Multiple companies across direct beneficiaries and supply chain stand to benefit.

source β†—